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ABSTRACT 
 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States, but few studies have examined the progression from HPV infection 
to disease in men.  Genital condyloma are the most common clinical manifestation of 
HPV infection.  Though not associated with mortality, condyloma are a source of 
emotional distress, and treatment is often painful with a high recurrence rate.  The aims 
of this study were to examine the distribution of HPV types present on the surface of 
condyloma, estimate the incidence of condyloma overall and after type-specific HPV 
infections, assess the sociodemographic and sexual behavior factors independently 
associated with incident condyloma, and examine the concordance between HPV types 
detected on the surface and in the tissue of condyloma.  Participants included 2,487 
men from the United States, Brazil, and Mexico who were enrolled in the prospective 
HPV in Men (HIM) Study and followed every six months for up to four years.  At each 
study visit men completed a computer-assisted-self-administered risk factor 
questionnaire and samples of healthy penile skin were obtained to test for HPV DNA.  A 
trained clinician examined men for the presence of condyloma and swabbed the surface 
of lesions to test for HPV DNA.  Men were followed for a median of 17.9 months and 112 
incident condyloma were identified.  Thirty-four external genital lesions were also 
biopsied to test for HPV within the lesion tissue.  PCR was used to test for HPV DNA 
and Linear Array was used to genotype 13 oncogenic and 24 non-oncogenic HPV types 
in samples obtained from swabbing the lesion surface.  The LiPa assay was used to 
genotype 20 HPV types in biopsy samples.  The Kaplan-Meier method was used to 
estimate incidence and Cox proportional hazards models were used to examine factors 
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independently associated with incident condyloma.  Using biopsy samples as the gold 
standard, sensitivity and specificity were calculated to examine concordance between 
HPV types detected on the surface and within the tissue of condyloma.  Condyloma 
incidence was 2.35 per 1,000 person-years.  HPV 6 (43.8%), 11 (10.7%), and 16 (9.8%) 
were the most common types detected on condyloma.  The probability of developing 
condyloma within 24-months of an incident HPV 6/11 infection was 14.6% (95% 
confidence interval (CI): 7.5-21.1).  The median time to condyloma development was 
17.1 months (95% CI: 12.4-19.3), with the shortest time to detection observed among 
men with incident HPV infections with types 6/11 only (6.2 months; 95% CI: 5.6-24.2).  
Factors associated with condyloma were incident HPV 6/11 infection (hazard ratio 
(HR)=12.42; 95% CI: 3.78-40.77), younger age (HR=0.43; 95% CI: 0.26-0.77; 45-70 vs. 
18-30 years), high lifetime number of female partners (HR=5.69; 95% CI: 1.80-17.97); 
≥21 vs. 0), and sexual behaviors in the previous three months including infrequent 
condom use (HR=2.44; 95% CI: 1.16-5.14; <half the time vs. always), number of male 
sexual partners (HR=4.53; 95% CI: 1.68-12.20; ≥3 vs. none), frequent vaginal 
intercourse (HR=4.14; 95% CI: 1.32-13.01); ≥21 times vs. none), having a partner with 
condyloma (HR=2.38; 95% CI: 1.01-5.61), and being diagnosed with a sexually 
transmitted infection (HR=1.99; 95% CI: 1.17-3.39).  HPV 6/11 plays an important role in 
condyloma development with the highest incidence and shortest time to condyloma 
development observed among men with incident HPV 6/11 infections.  Recent sexual 
history was also strongly associated with incident condyloma in men, suggesting that 
prevention efforts targeting behavioral modification may be effective at reducing 
condyloma incidence among men who are not vaccinated.  Samples obtained from the 
surface of condyloma lesions were both sensitive and specific as markers for the 
presence of any HPV, HPV6 and HPV11 in condyloma tissue, suggesting that sampling 
 vii 
the surface of condyloma is a non-invasive and accurate marker of the HPV types 
present within the tissue. 
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CHAPTER 1: INTRODUCTION 
 
STUDY PURPOSE 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States (US), with an estimated 6.2 million new cases each year [1].  HPV is 
an established cause of cervical cancer and is also associated with cancers of the 
oropharynx, anus, penis, vulva and vagina [2].  Over 100 HPV types have been 
identified and approximately 40 of these types infect the anogenital region.  HPV types 
are classified as oncogenic types (e.g. 16, 18, 31, and 45) that are associated with 
intraepithelial neoplasia and invasive carcinoma, and non-oncogenic types (e.g. 6 and 
11) that are associated with benign conditions such as condyloma.  
Estimates of the prevalence of HPV in men has been as high as 73%.   Recent 
studies of men in the US have reported that approximately 50% of men are positive for 
at least one known HPV type, and an additional 10-15% are positive for one or more 
unknown HPV types [3-5].  The probability of acquiring a new HPV infection over a 12-
month period is 29-39% [3, 5, 6].  Incidence of HPV infection is not associated with age 
in men and remains consistent across the lifespan [3].   
The majority of HPV infections are asymptomatic with an estimated 70% of 
incident infections clearing within one year [7].  Persistent infections can progress to 
disease and anogenital condyloma is the most common clinical manifestation of HPV 
infection [8].  Though condyloma are not associated with mortality, they are a source of 
physical discomfort, emotional distress and reduced quality of life [9, 10].  Condyloma 
have a high transmission rate between sexual partners; approximately 65% of 
individuals who have a sexual partner with condyloma will develop condyloma 
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themselves [11].  Treatment is often ineffective with about one-fourth of cases recurring 
within 3 months of treatment [12].  The high recurrence rate is associated with high 
medical costs; approximately $200 million is spent annually in the US to treat condyloma 
[13].   
The quadrivalent vaccine Gardasil, which protects against HPV types 6, 11, 16, 
and 18, was approved in October 2009 by the U.S. Food and Drug Administration for 
use in males ages 9 to 26.  Clinical trials have shown the vaccine to be effective at 
reducing the incidence of HPV infection and condyloma in men ages 16-26 [14].  
Incidence rates of condyloma and estimates of time from HPV infection to condyloma 
detection are necessary parameters for modeling the effectiveness of prevention through 
vaccination.  
To date, most research on the progression of HPV infection to disease has 
focused on women.  Little is known about the natural history of HPV related disease in 
men, including incidence of condyloma, the prevalence of HPV types within condyloma, 
the proportion of type-specific HPV infections that progress to condyloma, and the time 
from an HPV infection to development of condyloma.  Since male genital lesions are 
reservoirs for HPV infection, understanding the natural history of HPV related genital 
disease in men has the potential to not only reduce the burden of male disease, but also 
reduce the rate of HPV transmission to women. 
Current incidence rates for condyloma among US men are based on data from 
private insurance claims [15-17].  These data likely underestimate true incidence since 
they exclude individuals who do not seek treatment or who are not privately insured.  
Likewise, little is known regarding the median time from HPV infection to condyloma 
detection with only one published study to date conducted among young university 
students positive for HPV 6/11 [18].  Likewise, only a few studies have examined sexual 
behavioral factors associated with the development of condyloma in men [19-22], and 
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most of these studies were among highly selective populations including STI clinic 
attendees [20, 21] and men who have sex with men [22].  Similarly, many studies 
examining risk factors for condyloma in women have also been in select populations 
such as university students [23], STI clinic attendees [20], and young women in the 
placebo arm of an HPV vaccine trial [24].  Given that treatment of condyloma is often 
ineffective, it is important to identify modifiable behavioral factors for prevention efforts, 
especially among individuals who do not receive vaccination.  
Sampling methods can influence prevalence estimates of HPV types present in 
condyloma.  Current standard practice is to diagnose condyloma by visual inspection, 
and biopsy samples are not often obtained to confirm the diagnosis [25].  As a result, 
studies that include individuals from a standard clinic setting sample the surface of 
condyloma lesions to estimate the prevalence of HPV genotypes in the lesion tissue [26-
28].  It is possible that the HPV types detected on the surface of lesions may not 
represent the types present in the lesions themselves.  Assessing whether sampling the 
surface of a condyloma lesion provides an accurate measure of the HPV types present 
within the tissue of the condyloma could provide support as to whether it is necessary to 
biopsy a condyloma to accurately estimate the prevalence of HPV types in the lesion.    
 
SPECIFIC AIMS 
The goal of this research is to examine the progression of HPV infection to 
condyloma development in men.  The proposed research will be based on a sub-cohort 
of 2,487 men enrolled in the HPV in Men (HIM) Study.  The HIM Study is a prospective 
study that examines the natural history of anogenital HPV infection in men ages 18-70 
from the US, Brazil, and Mexico.  The specific aims of this research are: 
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1.  Estimate the incidence of condyloma, describe the prevalence of HPV types detected 
in incident condyloma and measure the time from type specific incident HPV 
infections to condyloma detection. 
2.  Identify sociodemographic and sexual behavioral factors associated with the 
incidence of condyloma.   
3.  Examine the concordance between HPV types detected on the surface and in the 
tissue of histologically confirmed anogenital condyloma.  
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CHAPTER 2: FIRST MANUSCRIPT: INCIDENCE AND HPV TYPE DISTRIBUTION OF 
CONDYLOMA IN A MULTINATIONAL COHORT OF MEN: THE HIM STUDY 
 
ABSTRACT 
Background: Data on the natural history of human papillomavirus (HPV) infection 
progression to genital warts (GW) in men are sparse.  We described the distribution of 
HPV types in incident GW and estimated GW incidence and time from type-specific 
incident HPV infections to GW detection in a multinational cohort of men ages 18-70.  
Methods: Participants included 2,487 men examined every 6 months and followed for a 
median of 17.9 months.  Samples obtained from 112 incident GW were tested for HPV 
DNA by PCR. Genotyping tested for the presence of 37 HPV types.   
Findings: Incidence of GW was 2.35 per 1,000 person-years with the highest incidence 
rate observed among men ages 18-30 (3.43 per 1,000 person-years).  HPV 6 (43.8%), 
11 (10.7%), and 16 (9.8%) were the most common types detected in GW.  The 24 month 
cumulative incidence of GW among men with incident HPV 6/11 infections was 14.6% 
(95% CI: 7.5-21.1).  The median time to any GW detection was 17.1 months (95% CI: 
12.4-19.3), with the shortest time to detection observed among men with incident 
infections with HPV 6/11 only (6.2 months; 95% CI: 5.6-24.2). 
Interpretation: HPV 6/11 plays an important role in GW development with the highest 
incidence and shortest time to GW development observed among men with incident 
HPV 6/11 infections.     
Funding:  National Cancer Institute.   
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INTRODUCTION  
 Anogenital human papillomavirus (HPV) is the most common sexually 
transmitted infection in the United State (US) [1].  Over 100 HPV types have been 
identified and approximately 40 of these infect the anogenital region.  Genital warts 
(GW) are a common HPV related disease associated with HPV types 6 and 11 [12].  In 
the US, 5.6% of sexually active adults ages 18-59 have self-reported ever being 
diagnosed with GW [29] and 1% of US adults ages 18-45 are estimated to have GW at 
any given time [30].  Though GW are benign and not associated with mortality, they are 
a source of psychosocial distress [9] and can cause physical discomfort including pain, 
bleeding and itching [25].  GW are highly infectious; 65% of people who have sex with a 
partner with GW will develop GW themselves [11].  A high rate of recurrence makes 
treatment difficult and costly [31].  Approximately $200 million is spent annually in the US 
for GW treatment [13].   
 HPV vaccination may be an effective approach for primary prevention of GW 
[32].  However, incidence rates for GW and estimates of time from HPV infection to GW 
detection are necessary parameters for modeling the effectiveness of GW prevention 
through vaccination.  Few published studies have reported the HPV type distribution in 
GW [26-28, 33], the incidence of GW [15-17], and the time from HPV infection to GW in 
men [18].  Most published incidence rates of GW for US men are based on data from 
private insurance claims [15-17].  These data likely underestimate true incidence since 
they exclude individuals who do not seek treatment or who are not privately insured.  
Likewise, little is known regarding the median time from HPV infection to GW detection 
with only one published study to date conducted among young university students 
positive for HPV 6/11 [34]. 
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The purpose of this study was to describe the prevalence of HPV types detected 
in newly acquired GW and estimate GW incidence and time from type specific incident 
HPV infections to GW detection in a multinational cohort of men ages 18-70.  
 
METHODS  
Study population 
 The HPV in Men (HIM) Study is a multinational prospective study of men ages 
18-70 that examines the natural history of HPV infection in men.  Participants were 
enrolled into the HIM Study between July 2005 and September 2009 and met the 
following inclusion criteria: (a) 18-70 years old; (b) resided in Southern Florida, US, Sao 
Paulo, Brazil or the state of Morelos, Mexico; (c) reported no previous diagnosis of 
penile or anal cancer; (d) reported no prior diagnosis of genital or anal warts; (e) had not 
participated in an HPV vaccine clinical trial; (f) reported no prior diagnosis of HIV or 
AIDS; (g) were not currently being treated for an STI; (h) had not been imprisoned, 
homeless or in drug treatment in the previous 6 months; and (i) were willing to complete 
10 scheduled visits every six months over four years.  
 In the United States, men were recruited from a large university and the general 
population in Tampa, FL via flyers, brochures and advertisements in local and university 
newspapers.  In Brazil, men were recruited from the general population of the 
metropolitan area of São Paulo through several advertisements and from a large 
urogenital care clinic.  Participants in Brazil also included the partners of healthy women 
who had participated in an HPV natural history study in Sao Paulo.  In Cuernavaca, 
Mexico, men were recruited through a state health plan, from local factories, and from 
the military.  All participants provided written informed consent and study protocols were 
approved by Institutional Review Boards at each study site.  A more detailed description 
of the study design and population has been reported previously [3, 4, 35].  The present 
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study includes 2,487 men who enrolled in the HIM Study before January 1, 2009, did not 
have GW detected at enrollment, and  completed at least one 6-month follow-up visit. 
Genital wart identification 
 GW were identified by visual inspection of the external genitalia by a trained 
clinician at each clinic visit.  All GW were sampled with a saline pre-wetted Dacron swab 
for the presence of HPV DNA.  If multiple GW were detected, a separate specimen was 
obtained from each lesion.  Specimens were also obtained from healthy genital skin on 
the coronal sulcus/glans penis, penile shaft, and scrotum for HPV DNA testing.  GW 
were sampled before healthy genital skin to avoid inter-specimen contamination.  
Lesions that appeared to be related to Herpes Simplex Virus or a benign condition such 
as skin tags or cysts were not sampled for HPV DNA.   
HPV DNA testing 
 DNA was extracted from samples using the QIAamp Mini kit following the 
manufacturer’s instructions (Qiagen, Valencia, CA).  The polymerase chain reaction 
(PCR) consensus primer system PGMY 09/11 was used to amplify a fragment of the 
HPV L1 gene.  Every PCR plate included a negative (H2O) and a positive (CaSki cell 
DNA) control to test for possible contamination.  The Linear Array HPV Genotyping Test 
(Roche Diagnostics, Indianapolis, IN) was used to test for the presence of 37 HPV types, 
including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) and 
24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67–73, 81–84, IS39, 
and CP6108).  A sample was considered HPV positive if HPV DNA was detected by 
PCR or it tested positive for at least one of the 37 HPV genotypes.  Samples that 
amplified HPV DNA by PCR but did not test positive for a specific HPV genotype were 
considered unclassified infections.  Beta-globin was detected in 93% (112/120) of GW 
samples.  The eight men with β-globin negative GW samples were excluded from all 
analyses. 
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Statistical analysis   
 GW incidence rates were calculated by dividing the number of incident cases by 
the number of person-months of follow-up.  Person-months were measured as the 
number of months from the date of enrollment until the date the incident GW was 
detected, or until the date of the last clinic visit for men who did not develop GW.  
Incidence rates were calculated for individual HPV types and groups of HPV types (non-
oncogenic or oncogenic HPV types) detected on the surface of the GW.  The 95% 
confidence intervals (CIs) for incidence rates were calculated based on the Poisson 
distribution [36].  All incidence rates were reported per 1,000 person-years.    
The Kaplan-Meier method was used to estimate the 12 and 24 month cumulative 
incidence of GW and the corresponding 95% CIs overall, by age group, and among men 
with type specific incident HPV infections.  Incident HPV infections were infections 
detected at a follow-up visit after a man tested negative for the same HPV type at 
enrollment.  Men who did not develop GW were censored at the date of their last study 
visit.  The log-rank test was used to test for differences in risk of GW by age group (18-
30 years; 31-44 years; and 45-70 years) and by type of incident HPV infection (HPV 
6/11 only; HPV 6/11 and other types; and HPV types other than 6/11).  Among the 112 
men who developed GW, the median time from type specific incident HPV infections to 
GW detection was calculated as time in months from the date an incident HPV infection 
was detected until the date the GW was detected.   
Role of the funding source  
Study sponsors had no role in the study design, data collection or analysis.  The 
corresponding author had full access to all data in the study and had final responsibility 
for the decision to submit for publication. 
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RESULTS 
 Study participants were followed for a median of 17.9 months (range, 4.5-46.9; 
25th – 75th percentiles, 7.0-29.6), with112 incident cases of GW detected during follow-
up.  The mean age of participants was 32.6 years (standard deviation (SD), 11.4; range, 
18-70), with 49% of men ages 18 to 30.  Forty-five percent of men self-reported White 
race and 45.2% self-identified as Hispanic.  At baseline, 64.8% of men tested positive for 
HPV DNA on the normal genital skin and 5.0% tested positive for HPV types 6 or 11 
(data not shown).        
Table 1 presents GW incidence rates and the distribution of HPV type groups 
(oncogenic versus non-oncogenic) detected on the surface of GW.  The overall 
incidence rate for a newly acquired GW was 2.35 per 1,000 person-years and HPV DNA 
was detected in 80.4% of GW.  Forty-two percent of GW had non-oncogenic HPV types 
only and HPV 6 and/or 11 was detected in 53.6% of the 112 incident GW and 66.7% of 
the 90 GW that tested positive for HPV DNA.  Five percent of GW tested positive for 
oncogenic HPV types only and HPV 16/18 was detected in 12.5% of GW.  Almost half of 
GW tested positive for multiple types of HPV (45.5%) and 27.7% of GW tested positive 
for a mix of oncogenic and non-oncogenic HPV types.  Unclassified infections that tested 
positive for HPV DNA by PCR but did not hybridize a specific HPV type occurred in 5.4% 
of GW.   
 Table 2 presents HPV type specific incidence rates and the proportion of GW 
that tested positive for specific HPV types.  Non-oncogenic types HPV 6 (43.8%) and 
HPV 11 (10.7%) were the most common types detected and had the highest incidence 
rates (1.03 per 1,000 person-years and 0.25 per 1,000 person years, respectively).  All 
other HPV types were found in ≤10% of GW and had incidence rates of <1.0 per 1,000 
person-years.  Other common non-oncogenic HPV types detected were 62 (9.8%; 0.23 
per 1,000 person-years) and 84 (8.9%; 0.21 per 1,000 person-years).  The most 
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common oncogenic HPV types detected were 16 (9.8%; 0.21 per 1,000 person-years) 
and 52 (6.2%; 0.15 per 1,000 person-years).  58.9% of men who developed GW had an 
HPV infection at a study visit prior to GW development with one or more of the same 
HPV types detected on the surface of the GW.  65.3% of men with GW positive for HPV 
6 and 58.3% of men with GW positive for HPV 11 had a preceding HPV infection with 
types 6 and 11, respectively (data not shown).    
 The cumulative risk of developing GW was 1.7% (95% CI: 1.2-2.3) at 12 months 
and 5.2% (95% CI: 4.1-6.4) at 24 months and the median time until detection of any GW 
regardless of HPV status was 17.1 months (95% CI: 12.4-19.3 months) (Table 3).  
Among men with an incident HPV infection with any type, cumulative incidence of GW 
was 2.4% (95% CI: 1.6-3.3) at 12 months and 6.8% (95% CI: 5.0-8.6) at 24 months.  
Though not statistically significant, cumulative incidence at 12 months was higher among 
men with incident HPV infections with non-oncogenic types only (4.1%; 95% CI: 2.2-6.0) 
compared to men with incident infections with oncogenic types only (1.8%; 95% CI: 0.0-
3.5), or a mix of oncogenic and non-oncogenic types (1.5%; 95% CI: 0.5-2.4) (p=0.39).  
Men with an incident HPV 6/11 infection had the highest probability of developing GW 
(Figure 1).  Twelve months after an incident HPV infection, 8.9% (95% CI: 0.0-18.1) of 
men with HPV 6/11 only, 5.2% (95% CI: 1.8-8.5) of men with HPV 6/11 and other types, 
and 2.5% (95% CI: 1.5-3.4) of men with HPV types other than 6/11 developed GW.  The 
probability of developing GW over 24-months was significantly higher among men with 
an HPV infection that included HPV types 6/11 (14.6%; 95% CI: 7.5-21.1) than men with 
an HPV infection not positive for types 6/11 (5.5%; 95% CI: 3.8-7.3) (p<0.0001) (Figure 
1, Table 3).  Time to GW detection was also shorter among men with an HPV infection 
with type 6/11 only (6.2 months, 95% CI: 5.6-24.2), and among men with an HPV 
infection with 6/11 and other HPV types (13.3 months; 95% CI: 6.3-19.6) than among 
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men with an HPV infection with HPV types other than 6/11 (18.2 months; 95% CI: 12.4-
23.6). 
Incidence of GW significantly varied across age groups (p-value <0.0001) (Figure 
2).  Although the 24 month cumulative incidence of GW was highest in younger men 
(7.4%; 95% CI: 5.4-9.4), mid adult (3.1%; 95% CI: 1.6-4.6) and older men (3.3%; 95% 
CI: 0.9-5.6) remained at risk for GW and the shortest time to GW detection was 
observed among men ages 45-70 (Table 4). There were no significant differences in GW 
incidence across countries within each age group (data not shown).  
 
DISCUSSION       
In this multinational cohort of men ages 18-70 we estimated GW incidence, time 
from HPV infection to GW detection, and described the distribution of HPV types 
detected on the surface of incident GW.  Men with incident HPV 6/11 infections had the 
highest incidence of GW and shortest time from HPV infection to GW detection.  HPV 6 
(43.8%) and 11 (10.7%) were the most common types detected on GW, but there was 
also a high prevalence of oncogenic types including HPV 16 (9.8%).   
 The incidence rate of GW among all men in our study was 2.35 per 1,000 
person-years, with the highest incidence of 3.43 per 1,000 person-years observed 
among men ages 18-30.  Our findings are similar to incidence estimates from studies 
using private health insurance claims that reported GW incidence rates of 1.70 [16], 1.62 
[17], and 1.10 [15] per 1,000 person-years.  Those studies also observed the highest 
GW incidence among younger men.  Two studies observed peak GW incidence among 
men ages 25-29 (5.01 per 1,000 person-years [15] and 2.7 per 1,000 person-years [16]), 
and one study observed the highest incidence among men ages 20-29 (3.1 per 1,000 
person-years [17]).  Higher GW incidence rates have been observed among individuals 
in the placebo arms of HPV vaccine clinical trials: 8.7 per 1,000 person-years among 
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females ages 15-26 [24] and 15.8 per 1,000 person-years among males ages 16-26 
[32].  An enrollment criterion for the clinical trials was having four or fewer lifetime sexual 
partners.  The median number of lifetime sexual partners in the current study was six, 
thus the lower GW incidence observed in the current study versus the clinical trials is 
unexpected.  One possible explanation is that young individuals just beginning to be 
sexually active, and therefore exposed to HPV for the first time, have not developed the 
immune response to clear an HPV infection and therefore are at higher risk of 
developing GW.  Time to clearance of an HPV infection is significantly longer in younger 
men [3], who may consequently have a greater likelihood of developing a lesion.   
   Approximately 15% of men in the current study developed GW within 24 months 
of an incident HPV 6/11 infection.  This is lower than a cohort of university students in 
which 58% of males [18] and approximately 60% of females [23] developed GW within 
24 months of an incident HPV 6/11 infection.  The age distribution of participants in each 
study may partially account for the difference. The student cohort only included 
individuals 18-21 while our study included men ages 18-70.  However, the 24 month 
cumulative incidence of GW after an incident HPV 6/11 infection was only 22.5% among 
men ages 18-21 in our study.  Differences in time intervals between clinic visits may also 
contribute to our lower observed GW incidence.  Men in our study had a slightly longer 
time of six months between visits compared to the cohort of students who were 
examined every four months.  Given that the median time to clearance of GW was 5.9 
months in the female students [23], it is possible there were men in our study who 
developed and cleared an incident GW between the 6-month clinic visits.   
Among men in our study with an incident HPV 6/11 infection, the median time to 
GW detection was 12.2 months, similar to the median time of 11.0 months reported 
among male university students with an incident HPV 6/11 infection [18].  Women 
appear to have a shorter time from HPV 6/11 infections to GW detection; the placebo 
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arm of a vaccine trial in women reported median times of 5.0 months [24] and the study 
of female university students reported a median time of 2.9 months [23].  It is not known 
why GW develop more slowly in men, but this observation is consistent with findings of 
peak GW incidence occurring at a slightly older age in men than in women [15, 16].  
The prevalence of HPV 6/11 in GW in our study was 54%.  Previous studies 
reported the HPV 6/11 prevalence in GW to be 86% among young women in the 
placebo arm of an HPV vaccine trial [24], 89% in men from Hong Kong [26], 90% among 
French men ages 18-72 [27], and greater than 95% in two small US studies that 
included fewer than 50 men [28, 33].  The lower than expected prevalence of HPV 6/11 
observed in GW in the current study may be the result of misclassification.  Preliminary 
biopsy data collected from a small sample of lesions identified in the HIM Study found 
39% of lesions diagnosed as GW by visual inspection were not true GW by pathology.  
The high rate of false positives suggests that non-condyloma skin conditions were 
classified as condyloma based on visual inspection and therefore were not positive for 
HPV 6/11.  We also observed a high proportion of oncogenic HPV types in GW (33.1%), 
with HPV 16 (9.8%) being the most common type detected after HPV 6 (43.8%) and 
HPV 11 (10.7%).  This finding is consistent with other studies that also reported a high 
prevalence of oncogenic HPV types in GW [24, 26, 27, 33].         
The major limitation of this study was reliance on visual inspection to identify 
GW.  Without pathological confirmation that lesions were GW, it is possible that non-
HPV related skin conditions were incorrectly classified as GW.  The lower than expected 
prevalence of HPV 6/11 and the slightly higher incidence rates of GW compared to 
previous studies [15-17] suggests some misclassification is present.  The generalizability 
of our findings may also be limited, since men who agree to participate in a four-year 
study are likely not representative of the underlying population at each study site.  
However, our findings are likely more generalizable to a broader population than findings 
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from clinical trials, which have a more select group of individuals due to more stringent 
selection criteria.  Also, HPV detection in the current study was based on samples 
obtained by sampling the surface of the GW, and therefore, the types detected may not 
represent the types present in the lesions themselves.  However, a small sample of 
histologically confirmed condyloma from the HIM Study found swabbing the surface of 
the lesion was a highly sensitive and specific method for detecting the HPV types 
present within the condyloma tissue [37].       
The major strength of the current study was the longitudinal study design and 
long duration of follow-up.  Repeated measures of HPV status over follow-up enabled 
the examination of how time to GW development differed after incident HPV infections 
with specific types.  We also included men from a broader age range than most previous 
studies, which allowed us to examine how incidence of GW differed with age.       
This study is one of the first to examine progression from HPV infection to GW 
including men from across the lifespan.  Though younger men had the highest incidence 
of GW mid-adult and older men still remained at risk of acquiring GW.  HPV 6/11 
appears to play an important role in GW development with the highest incidence and 
shortest time to GW development observed among men with incident HPV 6/11 
infections.  Future studies should confirm these incidence estimates among histologically 
confirmed GW.      
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Table 2.1.  Genital wart incidence by grouped HPV types detected on the 
surface of the lesion. 
HPV type detected on surface of GW n (%)a 
Incidence per 1,000 
person-years 
 (95% Confidence 
Interval) 
   
Incidence of GW regardless of HPV type 
detected on the lesion 112 (100.0) 2.35 (1.94-2.83) 
   
Positive for  HPVb 90 (80.4) 1.89 (1.52-2.33) 
   
Non-oncogenic HPV types only 47 (42.0) 0.99 (0.73-1.31) 
HPV 6/11  60 (53.6) 1.26 (0.96-1.62) 
Oncogenic HPV types only 6 (5.4) 0.13 (0.05-0.27) 
HPV 16/18 14 (12.5) 0.29 (0.16-0.49) 
   
Both non-oncogenic and oncogenic HPV types 31 (27.7) 0.65 (0.44-0.93) 
Positive for multiple HPV types 51 (45.5) 1.05 (0.78-1.39) 
   
Unclassified infectionsc 6 (5.4) 0.13 (0.05-0.27) 
 
  
aDenominator is the 112 men who developed incident GW. 
bIncludes unclassified HPV infections. 
bInfections that tested positive for HPV DNA by PCR but did not test positive for any 
of the 37 HPV types. 
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Table 2.2. Genital wart incidence by individual HPV types detected on the 
surface of the lesion. 
 
No. men who developed 
GW with HPV type  
n (%)a,b 
Incidence of GW per  
1,000 person-years 
(95% Confidence Interval) 
Non-oncogenic HPV 
  
6 49 (43.8) 1.03 (0.76-1.36) 
11 12 (10.7) 0.25 (0.13-0.44) 
26 0 (0.0) - 
40 7 (6.2) 0.15 (0.06-0.30) 
42 6 (5.4) 0.13 (0.05-0.27) 
53 8 (7.1) 0.17 (0.07-0.33) 
54 5 (4.5) 0.11 (0.03-0.25) 
55 7 (6.2) 0.15 (0.06-0.30) 
61 2 (1.8) 0.04 (0.01-0.15) 
62 11 (9.8) 0.23 (0.12-0.41) 
64 0 (0.0) - 
67 1 (0.9) 0.02 (0.00-0.12) 
68 3 (2.7) 0.06 (0.01-0.18) 
69 0 (0.0) - 
70 0 (0.0) - 
71 2 (1.8) 0.04 (0.01-0.15) 
72 2 (1.8) 0.04 (0.01-0.15) 
73 1 (0.9) 0.02 (0.00-0.12) 
81 1 (0.9) 0.02 (0.00-0.12) 
82 1 (0.9) 0.02 (0.00-0.12) 
83 2 (1.8) 0.04 (0.01-0.15) 
84 10 (8.9) 0.21 (0.10-0.39) 
IS39 0 (0.0) - 
CP6108 7 (6.2) 0.15 (0.06-0.3) 
Oncogenic HPV 
  
16 11 (9.8) 0.21 (0.10-0.39) 
18 4 (3.6) 0.08 (0.02-0.22) 
31 1 (0.9) 0.02 (0.00-0.12) 
33 0 (0.0) - 
35 0 (0.0) - 
39 5 (4.5) 0.11 (0.03-0.25) 
45 1 (0.9) 0.02 (0.00-0.12) 
51 6 (5.4) 0.13 (0.05-0.27) 
52 7 (6.2) 0.15 (0.06-0.30) 
56 1 (0.9) 0.02 (0.00-0.12) 
58 4 (3.6) 0.08 (0.02-0.22) 
59 5 (4.5) 0.11 (0.03-0.25) 
66 6 (5.4) 0.13 (0.05-0.27) 
aDenominator is the 112 men who developed incident GW. 
bPercentages do not sum to 100 due to men having multiple HPV types and being 
included in multiple HPV categories..  
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Table 2.3. Cumulative incidence of genital warts at 12 and 24 months and median time from incident HPV infection 
to genital wart detection. 
Incident HPV infection genotypea 
12 month cumulative 
incidence, % 
(95% CI) 
24 month cumulative 
incidence, % 
(95% CI) 
Median time in months 
from HPV infectiona to 
GW detection  
 (95% CI) 
Incidence of GW regardless of HPV status 1.7 (1.2-2.3)b 5.2 (4.1-6.4)b 17.1 (12.4-19.3)c 
Negative for HPV 1.1 (0.1-2.2) 1.8 (0.1-3.5) N/A 
Positive for HPV 2.4 (1.6-3.3) 6.8 (5.0.-8.6) 12.6 (12.1-18.4) 
Non-oncogenic HPV types only 4.1 (2.2-6.0) 6.7 (3.9-9.4) 7.6 (6.2-12.2) 
Oncogenic HPV types only 1.8 (0.0-3.5) 5.5 (0.9-9.9) 19.4 (6.2-23.5) 
Both non-oncogenic and oncogenic HPV types 1.5 (0.5-2.4) 6.8 (4.3-9.3) 18.8 (12.7-23.9) 
IHPV 6/11d 5.8 (2.6-9.0) 14.6 (7.5-21.1) 12.2 (6.2-18.9) 
HPV 6/11 only   8.9 (0.0-18.1) 13.7 (0.0-25.8) 6.2 (5.6-24.2) 
HPV 6/11 and other HPV types 5.2 (1.8-8.5) 14.5 (6.7-21.7) 13.3 (6.3-19.6) 
HPV types other than 6/11 2.5 (1.5-3.4) 5.5 (3.8-7.3) 18.2 (12.4-23.6) 
Note: CI-confidence interval. 
aIncident HPV infection that occurred before development of GW.  
bCumulative incidence of GW among all 2,487 men regardless of HPV infection status. 
cMedian time from enrollment visit to GW detection. 
dIncludes incident HPV infections with 6/11 only and infections with 6/11 and other HPV types. 
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Table 2.4.  Cumulative incidence of genital warts at 12 and 24 months and median time to genital wart 
detection by age groups. 
 
 
Age group 
(years) 
Incidence per 1,000 
person-years 
(95% CI) 
12 month cumulative 
incidence-% 
(95% CI) 
24 month cumulative 
incidence-% 
(95% CI) 
Median time in months from 
incident HPV infection to GW 
detection  
 (95% CI) 
18-30 3.43 (2.72-4.27) 2.3 (1.4-3.2) 7.4 (5.4-9.4) 17.2 (12.3-19.5) 
31-44 1.37 (0.89-2.02) 1.0 (0.3-1.7) 3.1 (1.6-4.6) 18.9 (11.9-24.2) 
45-70 1.27 (0.55-2.51) 1.7 (0.2-3.2) 3.3 (0.9-5.6)                  7.6 (5.8-13.6) 
Note: CI-confidence interval. 
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Figure 2.1.  Cumulative probability of genital warts among men with 
incident HPV infections with HPV 6/11 only, HPV6/11 and other HPV types, 
and only HPV types other than 6/11. 
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Figure 2.2.  Cumulative probability of genital warts by age groups. 
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CHAPTER 3: SECOND MANUSCRIPT: RISK FACTORS FOR CONDYLOMA IN A 
MULTINATIONAL COHORT OF MEN: THE HIM STUDY 
 
ABSTRACT 
Background:  Little is known about the sociodemographic and sexual behavior factors 
associated with incident genital warts (GW) in men. 
 Methods:  A cohort of 2,487 men from the US, Brazil and Mexico were followed every 
6-months for a median of 17.9 months.  At each study visit men completed a 
questionnaire to obtain information on sexual behavior and a trained clinician identified 
GW by visual inspection and sampled for the presence of human papillomavirus (HPV).  
Cox proportional hazards models were used to examine factors independently 
associated with incident GW. 
Results:  Factors associated with GW were incident HPV 6/11 infection (hazard ratio 
(HR)=12.42; 95% confidence interval (CI): 3.78-40.77), younger age (HR=0.43; 95% CI: 
0.26-0.77; 45-70 vs. 18-30 years), high lifetime number of female partners (HR=5.69; 
95% CI: 1.80-17.97); ≥21 vs. 0), and sexual behaviors in the previous three months 
including infrequent condom use (HR=2.44; 95% CI: 1.16-5.14; <half the time vs. 
always), number of male sexual partners (HR=4.53; 95% CI: 1.68-12.20; ≥3 vs. none), 
frequent vaginal intercourse (HR=4.14; 95% CI: 1.32-13.01); ≥21 times vs. none), having 
a partner with GW (HR=2.38; 95% CI: 1.01-5.61), and being diagnosed with a sexually 
transmitted infection (HR=1.99; 95% CI: 1.17-3.39).   
Conclusion: HPV 6/11 and recent sexual behavior were most strongly associated with 
incident GW in men. 
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NTRODUCTION 
 
 Genital warts (GW) are one of the most prevalent sexually transmitted infections 
(STI) in the United States (US), and the incidence of GW has been increasing in the last 
decade [17].  Approximately 90% of GW are associated with human papillomavirus 
(HPV), particularly non-oncogenic HPV types 6 and 11 [27].  Though GW are not 
associated with mortality, they are a source of emotional distress and reduced quality of 
life [9, 10, 38].  GW have a high transmission rate between sexual  partners [11], and 
treatment of GW is often ineffective with about one-fourth of cases recurring within 3 
months of treatment [12].  Identifying factors associated with GW can contribute to 
prevention efforts that focus on behavioral modification.  
Only a few studies have examined the factors associated with the development 
of GW in men [19-22], and most of these studies were among highly selective 
populations including STI clinic attendees [20, 21] and men who have sex with men [22].  
Similarly, many studies examining risk factors for GW in women have also been in select 
populations such as university students [23], STI clinic attendees [20], and young 
women in the placebo arm of an HPV vaccine trial [24].  The purpose of this study was 
to identify sociodemographic and sexual behavioral factors associated with the incidence 
of GW in a cohort of men ages 18-70 residing in the US, Brazil, and Mexico.   
 
METHODS 
Study population 
 The HPV in Men (HIM) Study is a multinational prospective study of men ages 
18-70 that examines the natural history of HPV infection in men.  Participants were 
enrolled between July 2005 and September 2009 and met the following inclusion criteria: 
(a) were ages 18-70 years old; (b) resided in Southwest Florida, Sao Paulo, Brazil or the 
state of Morelos Mexico;  
 24
(c) reported no previous diagnosis of penile or anal cancer; c no prior diagnosis of 
genital or anal warts; (e) had not participated in an HPV vaccine clinical trial; (f) reported 
no prior diagnosis of HIV or AIDS; (g) were not currently being treated for an STI; (h) had 
not been imprisoned, homeless or in drug treatment in the previous six months; and (i) 
were willing to complete 10 scheduled visits every six months over four years.  
The current analysis included the first 2,487 men enrolled in the HIM study 
through January 1, 2009 who did not have GW detected at enrollment and completed at 
least one 6-month follow-up visit.  All participants provided written informed consent and 
study protocols were approved by Institutional Review Boards at each study site.  
Study design 
 Men completed a pre-enrollment run-in visit followed by an enrollment visit 
approximately two weeks later.  After enrollment, men returned approximately every six 
months for eight additional follow-up visits.  At each study visit participants completed an 
extensive risk factor questionnaire in their native language (English, Spanish, or 
Portuguese), administered using Computer-Assisted Self-Interviewing.  The survey 
obtained information about sociodemographic factors and lifetime and recent sexual 
behavior.    
At each clinic visit a trained clinician examined men for genital lesions.  GW were 
lesions with a wart-like architecture that did not appear to be related to Herpes Simplex 
virus or a benign condition such as pearly penile papules, skin tags, cysts, or  Fordyce 
spots.  Saline-prewetted Dacron swabs were used to obtain samples of healthy penile 
epithelium from the coronal sulcus/glans penis, penile shaft, and scrotum.  The three 
samples were combined for HPV DNA testing and genotyping.  A full description of study 
procedures has been published previously [3, 4, 35].  
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HPV DNA testing 
 Polymerase chain reaction (PCR) was used to test for HPV DNA. Following the 
instructions of the manufacturer (Qiagen, Valencia, CA), the QIAamp Mini kit was used 
to extract DNA from the skin swabs.  A fragment of the HPV L1 gene was amplified 
using the PCR consensus primer system PGMY 09/11.  The Linear Array HPV 
Genotyping Test (Roche Diagnostics, Indianapolis, IN) was used to test for 37 HPV 
types, including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
66) and 24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67–73, 81–84, 
IS39, and CP6108).  HPV genotyping was conducted on all samples, regardless of HPV 
PCR result.  A sample was classified as HPV positive if HPV DNA was detected by PCR 
or the sample tested positive for at least one of the 37 HPV genotypes tested for. 
Statistical analysis 
 The Pearson’s chi-squared test for categorical variables and the t-test for 
continuous variables were used to compare the baseline distribution of 
sociodemographic characteristics and sexual behavior factors between men with 
incident GW and men who did not develop GW.  Cox proportional hazard models were 
used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the 
association between incident and prevalent HPV infection and risk of GW.  An individual 
had an incident HPV infection for a specific HPV type if he tested negative for that type 
at enrollment and later tested positive for the same type at a follow-up visit.  Prevalent 
HPV infections were infections present at enrollment.  The reference group for all 
models assessing the association between HPV infection and GW was men who tested 
negative for HPV at all study visits.  Person-time was calculated as the months from the 
enrollment date until the date of the visit at which a GW was detected or until the last 
follow-up visit for men who did not develop GW. 
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Cox proportional hazard models were also used to examine crude and 
multivariable associations between sociodemographic and sexual behavior factors and 
the risk of developing GW.   The backward selection method, with a significance 
threshold of 0.05, was used to determine the factors included in the final multivariable 
model.  Variables initially included were:  race, ethnicity, marital status, education, 
cigarette smoking status, circumcision status, age at first intercourse with a female, 
lifetime and recent number of female and male sexual partners, sexual orientation, 
condom use, frequency of vaginal intercourse, having a steady female partner, ever 
being diagnosed with an STI, ever having a partner with an STI, ever having a partner 
with GW, and incident HPV 6/11 infection. Country of residence (US; Brazil; Mexico) and 
age (18-30 years; 31-44 years; 45-70 years) were study design factors and therefore 
included in all multivariable models.  Covariates that could change over the follow-up 
period, (e.g., recent number of female partners), were treated as time-dependent 
variables.  The final multivariable model was run including among all men in the cohort 
(n=2487) and then restricted to men who had an incident HPV infection of any type 
during follow-up (n=1498).  All p-values were 2-sided and considered significant if below 
0.05. Statistical analyses were conducted using SAS version 9.1.   
 
RESULTS           
Men were followed for a median of 17.9 months (range, 4.5-46.9; 25th – 75th 
percentiles, 7.0-29.6), and 112 men developed GW.  Table 1 compares the baseline 
distribution of sociodemographic and sexual behavior factors between men who 
developed GW and men who did not.  Compared to men who did not develop GW, men 
with incident GW were significantly younger, more likely to be White, current smokers, 
circumcised, have a high number of lifetime female sexual partners, have more female 
sexual partners in the previous three months, and not always use condoms.    
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Table 2 presents the associations between types of HPV infections and risk of 
subsequent GW.  The strongest associations were observed for infections with non-
oncogenic HPV types 6/11.  Compared to men who never tested positive for HPV, there 
was a significant increased risk for GW among men with an incident HPV infection with 
types 6/11 only (HR=12.42; 95% CI: 3.78-40.77) and among men with an incident 
infection with HPV 6/11 and other types (HR=7.74; 95% CI: 3.10-19.31).  Risk of GW 
was also significantly higher among men with an incident infection with non-oncogenic 
HPV types only (HR=3.63; 95% CI: 1.49-8.83) or a mix of non-oncogenic and oncogenic 
types (HR=3.94; 95% CI: 1.68-9.27).  There was no significant increased risk for GW 
among men with incident infections with oncogenic HPV types only (HR=2.42; 95% CI: 
0.56-6.86) or men with incident infections with HPV types other than 6/11 (HR=2.16; 
95% CI: 0.93-5.02).  Similar associations were observed for prevalent HPV infections at 
enrollment, with the highest risk for GW among men with an HPV infection with types 
6/11 only (HR=16.78; 95% CI: 5.97-47.19).          
Table 3 presents the risk of GW for factors that remained in the final multivariable 
model, while adjusting for HPV 6/11 infection, for the entire cohort (n=2,487) and 
restricted to men with an incident HPV infections (n=1,498).  For the entire cohort, the 
factors independently associated with risk of GW, while adjusting for infection with HPV 
6/11, were country, age, lifetime number of female sexual partners, recent condom use, 
recent number of male anal sex partners, frequency of vaginal intercourse in the past 
three months, ever having a partner with GW, and ever being diagnosed with an STI.  
Compared to men residing in the US, the risk of GW was lower for men living in Brazil 
(HR=0.33; 95% CI: 0.20-0.54) and Mexico (HR=0.45; 95% CI: 0.26-0.77).  Risk of GW 
decreased with age and was comparable among men ages 31-44 (HR=0.44; 95% CI: 
0.27-0.71) and 45-70 (HR=0.43; 95% CI: 0.20-0.92) compared to men ages 18-30.  
Compared to men who reported no female sexual partners in their lifetime, risk of GW 
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increased with an increasing number of female partners (p for trend: <0.0001).  The 
significant increase in risk however was only among men with six or more lifetime female 
partners.  Risk of GW was also significantly higher among men who refused to report 
lifetime number of female partners.  However, including these men in the model did not 
bias results, as there were no major differences in risk estimates when the multivariable 
model was run after excluding these 135 men (data not shown).  Sexual behaviors in the 
previous three months that were associated with an increased risk of GW were a high 
number of male anal sex partners (HR=4.53; 95% CI: 1.68-12.20 for men who reported 
three or more recent male partners compared to men with no recent male partners), 
more frequent vaginal intercourse (HR=4.14; 95% CI: 1.31-13.01 for ≥21 times 
compared to men who reported no vaginal intercourse in the recent past), and infrequent 
condom use (HR=2.44; 95% CI: 1.16-5.14 for using condoms less than half the time vs. 
always).  Ever being diagnosed with an STI (HR=1.99; 95% CI: 1.17-3.39) and ever 
having a partner with GW (HR=2.38; 95% CI: 1.01-5.61) also increased the risk of GW.   
The multivariable model was also run restricted to men with an incident HPV 
infection to examine which factors in addition to HPV were associated with incident GW 
(Table 3).  Factors that remained significantly associated with GW were country, age, 
lifetime number of female partners, recent condom use, and being diagnosed with an 
STI.  Recent number of male anal sex partners, frequency of vaginal intercourse in the 
previous three months, and having a partner with GW were not significantly associated 
with risk of GW among men with an incident HPV infection.             
 
DISCUSSION  
In this cohort of men ages 18-70 from the US, Brazil, and Mexico, HPV 6/11 
infections were most strongly associated with incidence of GW.  Recent sexual 
behaviors associated with incidence of GW were condom use, recent number of male 
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anal sex partners, frequency of vaginal intercourse, having a partner with GW, and 
testing positive for an STI.  This is the first study to use a prospective design to examine 
sexual behaviors associated with GW, thus minimizing recall bias that may have 
occurred in previous case-control studies.  The current study also includes men largely 
from the general community, making the results more generalizable than previous 
studies which included men from more select populations.     
In our cohort, men with incident HPV infections with only types 6/11 had the 
highest risk of developing GW.  Previous analyses of this cohort of men also found the 
highest incidence of GW and shortest time from HPV infection to GW detection among 
men with incident HPV 6/11 infections (data not shown).  The strong association 
between HPV 6/11 and GW has also been observed among females enrolled in the 
placebo arm of an HPV vaccine trial [24]; women who tested positive for HPV 6/11 at 
baseline were 29 times more likely to develop GW in the first year of follow-up compared 
to women negative for HPV 6/11.  The same study saw a significant increased risk for 
GW among women who had HPV infections with oncogenic types only.   We also saw 
an increased risk of GW among men with HPV infections with oncogenic types only at 
enrollment.  It is likely that the men with oncogenic infections at enrollment acquired a 
subsequent non-oncogenic HPV infection prior to GW development.   
 Consistent with the nature of a sexually transmitted disease, the risk of GW was 
highest among men with a high lifetime number of female sexual partners or more 
frequent vaginal intercourse.  The association between a high lifetime number of female 
partners and risk of GW was also observed in STI clinic attendees [20] and male 
members of a health maintenance organization [19].  A higher number of sexual partners 
and more frequent sexual intercourse increase a man’s chance of being exposed to 
HPV.  Having a high number of female partners [3, 35, 39, 40] and frequent sexual 
intercourse [39] are both significantly associated with HPV infection in men.  We also 
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observed a significant increased risk for GW among men who refused to report their 
lifetime number of female partners. These men likely had a high number of partners but 
did not provide an answer because they were not sure of the exact number or they were 
embarrassed to report a large number.      
 Always using condoms was protective against GW in our cohort.  Frequent 
condom use was also protective against GW in a study of STI clinic attendees [20], but 
no association was observed in a study of male health maintenance organization 
members [19].  Similarly, there have been inconsistent findings on the protective effect 
of condom use against HPV infection in men [41].  Condoms provide a protective barrier 
against the transmission of HPV by skin to skin contact; however, men can be infected 
with HPV on areas not protected by a condom.  We did not observe an increased risk for 
GW among the men who reported never using condoms in the recent past.  Frequent 
condom use may be a marker for engaging in high risk sexual behavior such as having 
multiple partners, while not using condoms may be a marker for low risk behavior such 
as being in a monogamous relationship.  The increased risk of GW among men 
reporting no vaginal sex in the last three months was likely due to the fact that this 
category included men who had one or more male anal sex partners in the recent past.   
Men who had three or more male anal sex partners in the previous three months 
had a significantly increased risk of GW compared to men with no recent male partners.  
This observation is consistent with results from a male vaccine trial in which men who 
had sex with men had an incidence rate of GW more than twice as high as men who 
only had sex with women [32].  However, lifetime number of male sexual partners was 
not associated with GW in our study.  We also did not observe an increased risk for GW 
among men with a high number of recent female partners, consistent with a study of STI 
attendees that found no association between GW and the number of sexual partners in 
the previous 12 months [21].  Having had a partner with GW significantly increased the 
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risk for GW.  This observation is consistent with the high transmission rate of GW 
between partners [11] and a finding that men with a female partner with GW are more 
likely to be HPV positive [42].   
Though age is not associated with incidence of HPV infection in men [3], we 
found the that risk of GW significantly decreased with age independent of sexual 
behavioral factors including lifetime number of female partners.  This age pattern has 
consistently been observed in other studies examining risk factors for GW in men [19-22] 
as well as GW incidence estimates based on data from US insurance claims [15-17].  
Changes in immune response with increasing age may be related to the lower incidence 
of GW in older men. Though the prevalence of HPV in men remains steady across the 
lifespan, older men clear HPV infections faster than younger men [3] and increasing age 
is associated with higher levels of antibodies against HPV types 6 and 11 [43].  More 
rapid clearance and a stronger immune response may reduce the likelihood that an HPV 
infection progresses to a lesion.   
There was a significantly reduced risk of GW among men in Brazil and Mexico 
compared to men in the US.  The difference in risk across countries may be partially due 
to residual confounding by age; country remained a significant factor when the final 
multivariable model was run among men ages 18-30, but the association with country 
did not remain significant in models restricted to men ages 31-44 or 45-70 (data not 
shown).  
There are limitations to the current study that should be considered when 
interpreting the results.  GW were identified by visual inspection, therefore 
misclassification may exist if lesions we classified as GW were actually a non-HPV 
related benign skin condition.  However, misclassification of GW would likely be non-
differential with respect to sexual behavior and, therefore, result in underestimates of the 
associations between GW and various risk factors.  The generalizability of our findings is 
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likely limited due to the self-selection of participants.  Men who agree to participate in a 
four year prospective study may not be representative of the underlying population from 
each country.  However, our results are likely more generalizable than studies that only 
included men who have sex with men or men who were seeking treatment for an STI.     
Strengths of our study included use of an extensive questionnaire to collect data 
for a variety of potential risk factors and a prospective study design that allowed us to 
obtain data on sexual behavior before men developed GW.  Previous studies of risk 
factors for GW in men were case-control studies that collected risk factor data after men 
were diagnosed with GW, potentially leading to biased results if being diagnosed with 
GW caused men to alter their sexual behavior (e.g., use condoms more frequently) or 
affected how accurately they recalled their sexual habits.  By collecting data on lifetime 
and recent sexual behavior before men were diagnosed with GW, recall bias was 
minimized.   
In summary, the factors independently associated with an increased risk of GW 
in this cohort of men ages 18-70 included incident HPV 6/11 infection, a high number of 
lifetime female or recent male sexual partners, frequent vaginal intercourse, infrequent 
condom use, having with a partner with GW and ever being diagnosed with an STI.  The 
strong association between recent sexual history and incident condyloma after 
accounting for HPV infection suggests that prevention efforts targeting behavioral 
modification may be effective at reducing condyloma incidence among men who are not 
vaccinated. 
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Table 3.1. Distribution of sociodemographic and sexual behavior characteristics of 
cohort members at enrollment. 
 
Genital Warts 
(N=112) 
n (%) 
No Genital 
Warts 
(N=2375) 
n (%) p-valuea 
Country    
United States 61 (54.5) 657 (27.7) <0.0001 
Brazil 31 (27.7) 935 (39.4)  
Mexico 20 (17.9) 783 (33.0)  
Age    
       18-30 79 (70.5) 1142 (48.1) <0.0001 
       31-44 25 (22.3) 903 (38.0)  
       45-70 8 (7.1) 330 (13.9)  
      Mean (SD) 28.5 32.8 <0.0001 
Race    
White 70 (62.5) 1046 (44.0) <0.01 
Black 16 (14.3) 385 (16.2)  
Asian/Pacific Islander 0 (0.0) 59 (2.5)  
American Indian 1 (0.9) 54 (2.3)  
Mixed/Mestizo 24 (21.4) 802 (33.8)  
Unknown/Refused 1 (0.9) 29 (1.2)  
Current smoker    
Yes 27 (24.1) 500 (21.1) 0.04 
No 84 (75.0) 1873 (78.9)  
Refused 1 (0.9) 2 (0.1)  
Circumcision (clinician assessed)    
Yes 65 (58.0) 774 (32.6) <0.0001 
No 47 (42.0) 1601 (67.4)  
Sexual orientation at enrollment    
Men who have sex with women only 98 (87.5) 1971 (83.0) 0.18 
Men who have sex with women and men 6 (5.4) 129 (5.4)  
Men who have sex with men only 5 (4.5) 113 (4.8)  
Never had sex 2 (1.8) 157 (6.6)  
Refused 1 (0.9) 5 (0.2)  
Lifetime no. of female sexual partners    
0 5 (4.5) 254 (10.7) <0.01 
1 6 (5.4) 205 (8.6)  
2 to 5 20 (17.9) 654 (27.5)  
6 to 10 28 (25.0) 463 (19.5)  
11 to 20 21 (18.8) 353 (14.9)  
≥21 24 (21.4) 319 (13.4)  
Refused 8 (7.1) 127 (5.4)  
Total no. of female partners in past 3 months    
None 17 (15.2) 813 (34.2) <0.0001 
1 49 (43.8) 934 (39.3)  
2 23 (20.5) 288 (12.1)  
≥3 21 (18.8) 271 (11.4)  
Refused 2 (1.8) 69 (2.9)  
No. of new female partners in past 3 months    
None 63 (56.3) 1506 (63.4) 0.08 
1 29 (25.9) 523 (22.0)  
2 9 (8.0) 124 (5.2)  
≥3 9 (8.0) 106 (4.5)  
Refused 2 (1.8) 116 (4.9)  
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Table 3.1. Distribution of sociodemographic and sexual behavior characteristics of 
cohort members at enrollment (Contd.). 
 
Genital Warts 
(N=112) 
n (%) 
No Genital 
Warts 
(N=2375) 
n (%) p-valuea 
Condom use during vaginal intercourse in 
past 3 months   
 
Always 27 (24.1) 436 (18.4) 0.03 
At least half the time 30 (24.8) 424 (17.9)  
<Half the time 16 (14.3) 279 (11.8)  
Never 26 (23.2) 732 (30.8)  
No vaginal sex in the past 3 months 13 (11.6) 475 (20.0)  
Refused 0 (0.0) 29 (1.2)  
No. of times of vaginal intercourse in past 3 
months   
 
None 19 (17.0) 696 (29.3) 0.07 
1 to 5 22 (19.6) 342 (14.4)  
6 to 20 30 (26.8) 566 (23.8)  
≥21 35 (31.3) 647 (27.2)  
Refused 6 (5.4) 124 (5.2)  
Lifetime no. of male anal sex partners    
None 97 (86.6) 2013 (84.8) 0.80 
1 3 (2.7) 99 (4.2)  
2 3 (2.7) 61 (2.6)  
≥3 7 (6.3) 180 (7.6)  
Refused 2 (1.8) 22 (0.9)  
No. of male anal sex partners in past 3 
months 
  
 
None 105 (93.8) 2218 (93.4) 0.70 
1 3 (2.7) 54 (2.3)  
2 0 (0.0) 25 (1.1)  
≥3 4 (3.6) 64 (2.7)  
Refused 0 (0.0) 14 (0.6)  
Ever had a partner with an STI    
Yes 27 (24.1) 372 (15.7) 0.12 
No 48 (42.9) 1181 (49.7)  
Don't know 37 (33..0) 821 (34.6)  
Refused 0 (0.0) 1 (0.1)  
Ever had a partner with genital warts    
Yes 9 (8.0) 120 (5.1) 0.34 
No 70 (62.5) 1582 (66.6)  
Don't know 33 (29.5) 673 (28.3)  
Refused 0 (0.0) 0 (0.0)  
Ever been diagnosed with an STI by a doctor    
Yes 22 (19.6) 387 (16.3) 0.08 
No 86 (76.8) 1923 (81.0)  
Don't know 3 (2.7) 63 (2.7)  
Refused 1 (0.9) 2 (0.1)  
aDifferences between groups was tested with the chi-squared test for categorical variables 
and  t-test for continuous variables. 
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Table 3.2. Independent association between HPV infection and risk of genital warts. 
 
Genital Warts 
(n=112) 
n (%) 
No  
Genital Warts 
 (n=2375) 
n (%) 
Hazard Ratio  
(95% Confidence 
Interval) 
    
No HPV infectiona 6 (5.4) 410 (17.3) 1.00 (ref) 
INCIDENT HPV INFECTIONS 
   
Any HPV type 80 (71.4) 1418 (59.7) 3.80 (1.65-8.73) 
Non-Oncogenic HPV types only 27 (24.0) 527 (22.2) 3.63 (1.49-8.83) 
Oncogenic HPV types only 9 (8.0) 290 (12.2) 2.42 (0.56-6.86) 
Both non-oncogenic and oncogenic types 44 (39.3) 601 (25.3) 3.94 (1.68-9.27) 
HPV 6/11b 25 (22.3) 199 (8.4) 7.95 (3.25-19.43) 
HPV 6/11 only 5 (4.5) 31 (1.3) 12.42 (3.78-40.77) 
HPV 6/11 and other HPV types 20 (17.9) 168 (7.1) 7.74 (3.10-19.31) 
HPV infection without types 6/11 55 (49.1) 1219 (51.3) 2.16 (0.93-5.02) 
   
 
PREVALENT HPV INFECTIONS   
 
Any HPV type 93 (83.0) 1518 (63.9) 3.31 (1.45-7.56) 
Non-Oncogenic HPV types only 21 (18.8) 491 (20.7) 2.34 (0.95-5.81) 
Oncogenic HPV types only 24 (21.4) 279 (11.8) 4.44 (1.81-10.88) 
Both non-oncogenic and oncogenic types 42 (37.5) 386 (16.3) 6.29 (2.67-14.80) 
HPV 6/11b 24 (21.4) 101 (4.3) 11.12 (4.54-27.21) 
HPV 6/11 only 9 (8.0) 20 (0.8) 16.78 (5.97, 47.19) 
HPV 6/11 and other HPV types 15 (13.4) 81 (3.4) 9.55 (3.70-24.63) 
HPV infection without types 6/11 69 (61.6) 1417 (59.7) 2.65 (1.15-6.11) 
    
aReference group for all models. 
bIncludes HPV infections with 6/11 only and infections with 6/11 and other HPV types. 
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Table3.3. Multivariable associations for sociodemographic and sexual behavior 
factors with genital wart incidence after accounting for HPV 6/11 infection. 
 
Crude  
HR (95% CI) 
Multivariable 
Entire cohort 
(N=2487) 
HR (95% CI)c 
Multivariable 
Men with 
incident HPV 
(N=1498) 
HR (95% CI)c 
Country    
United States 1.00 (ref) 1.00 (ref) 1.00 (ref) 
Brazil 0.44 (0.29-0.69) 0.33 (0.20-0.54) 0.32 (0.18-0.56) 
Mexico 0.39 (0.24-0.65) 0.45 (0.26-0.77) 0.26 (0.12-0.55) 
Age 
   
18-30 1.00 (ref) 1.00 (ref) 1.00 (ref) 
31-44 0.40 (0.25-0.62) 0.44 (0.27-0.71) 0.51 (0.29-0.89) 
45-70 0.38 (0.18-0.79) 0.43 (0.20-0.92) 0.28 (0.10-0.82) 
Lifetime no. female sexual 
partners    
   0 1.00 (ref) 1.00 (ref) 1.00 (ref) 
   1 1.63 (0.50-5.34) 1.84 (0.51-6.56) 2.18 (0.45-10.66) 
   2 to 5 1.72 (0.65-4.58) 2.26 (0.74-6.88) 2.94 (0.72-11.95) 
   6 to 10 3.45 (1.33-8.94) 4.30 (1.42-12.98) 4.71 (1.19-18.65) 
   11 to 20 3.29 (1.24-8.73) 4.37 (1.41-13.53) 6.00 (1.51-23.80) 
   ≥21 4.08 (1.55-10.70) 5.69 (1.80-17.97) 7.76 (1.91-31.49) 
  Refused 3.36 (1.10-10.28) 5.99 (1.73-20.72) 5.19 (1.06-25.27) 
     p for trend <0.0001 <0.0001 <0.001 
Condom use during vaginal 
intercourse in the past three 
monthsa    
Always 1.00 (ref) 1.00 (ref) 1.00 (ref) 
At least half the time 3.26 (1.66-6.44) 2.34 (1.17-4.69) 2.81 (1.13-6.96) 
Less than half the time 3.00 (1.45-6.20) 2.44 (1.16-5.14) 2.69 (1.03-7.01) 
Never 1.26 (0.62-2.57) 1.31 (0.63-2.71) 1.65 (0.64-4.24) 
No vaginal sex in the 
past three monthsb 1.34 (0.63-2.87) 4.25 (1.17-15.48) 4.70 (0.97-22.92) 
Refused 1.97 (0.44-8.89) 0.88 (0.05-16.38) 1.04 (0.02-58.41) 
No. male anal sex partners 
in past three monthsa  
  
None 1.00 (ref) 1.00 (ref) 1.00 (ref) 
1 1.26 (0.75-2.12) 1.10 (0.26-4.70) 1.25 (0.29-5.430) 
2 1.88 (0.93-3.79) 3.17 (0.71-14.07) 1.89 (0.24-14.75) 
≥3 2.75 (1.47-5.13) 4.53 (1.68-12.20) 2.60 (0.68-9.95) 
Refused 1.26 (0.66-2.38) 2.75 (0.71-10.75) 3.40 (0.79-14.59) 
No. of times of vaginal 
intercourse in past three 
monthsa 
   
None 1.00 (ref) 1.00 (ref) 1.00 (ref) 
1 to 5 1.15 (0.51-2.61) 2.13 (0.58-7.77) 1.57 (0.33-7.38) 
6 to 20 1.48 (0.79-2.78) 2.94 (0.90-9.57) 1.70 (0.42-6.97) 
≥21 2.28 (1.30-4.01) 4.14 (1.32-13.01) 2.99 (0.77-11.52) 
Refused 2.18 (1.03-4.61) 2.63 (0.87-7.96) 2.10 (0.54-8.16) 
Ever had a partner with genital wartsa 
  
No 1.00 (ref) 1.00 (ref) 1.00 (ref) 
Yes 2.81 (1.21-6.48) 2.38 (1.01-5.61) 2.40 (0.84-6.87) 
Don't know 2.89 (1.91-4.36) 2.34 (1.51-3.64) 2.50 (1.49-4.19) 
Refused 2.48 (0.61-10.16) 1.46 (0.08-26.46) 1.04 (0.02-56.5) 
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Ever been diagnosed with an 
STIa 
No 1.00 (ref) 1.00 (ref) 1.00 (ref) 
Yes 2.52 (1.51-4.20) 1.99 (1.17-3.39) 2.11 (1.15-3.87) 
Don't know 0.47 (0.07-3.40) 0.34 (0.05-2.51) 0 (0-.) 
Refused 2.02 (0.50-8.20) 1.46 (0.09-23.65) 1.10 (0.02-53.61) 
Note: HR - hazard ratio; CI - confidence interval; bolded results have p-values <0.05. 
a Time-dependent covariates. 
b Includes men who only had sex with men in the last three months. 
C Each factor is adjusted for incident HPV 6/11 infection and all other variables in the table. 
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CHAPTER 4: THIRD MANUSCRIPT: CONCORDANCE OF HUMAN 
PAPILLOMAVIRUS TYPES DETECTED ON THE SURFACE AND IN THE TISSUE OF 
CONDYLOMA IN MEN  
 
ABSTRACT 
The prevalence of HPV in condyloma has often been estimated by sampling the 
lesion surface, however, HPV types on the lesion surface may not represent the types 
present in the lesions themselves.  We examined the concordance between HPV types 
detected on the surface and in the tissue of condyloma in men.  Samples obtained from 
the surface of condyloma lesions were both sensitive and specific markers for the 
presence of any HPV, HPV6 and HPV11 in condyloma tissue.  Our results suggest that 
sampling the surface of condyloma lesions is a non-invasive and accurate marker of the 
HPV types present in condyloma tissue. 
 
INTRODUCTION 
Anogenital condyloma are the most common clinical manifestation of human 
papillomavirus (HPV) infection [12].  Current standard practice is to diagnose condyloma 
by visual inspection, and diagnosis is rarely confirmed by biopsy [25].  Thus, clinic-based 
HPV prevalence studies use samples from the surface of condyloma lesions to estimate 
the prevalence of HPV genotypes in the lesion tissue [26-28].  It is possible that the HPV 
types detected on the surface of lesions may not represent the types present in the 
lesions themselves.  Accurate estimates of the distribution of HPV types in condyloma 
are needed to model the efficacy of the quadrivalent HPV vaccine that protects against 
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HPV 6, 11, 16 and 18 and for use in the development of future vaccines that protect 
against additional HPV types.   
Since biopsying anogenital condyloma is invasive and may deter individuals from 
participating in studies that examine the prevalence of HPV types in anogenital lesions, it 
is important to determine whether sampling the surface of a lesion provides an accurate 
measure of the HPV types present within it.  The purpose of this study was to examine 
the concordance between HPV types detected on the surface and in the tissue of 
condyloma and non-condyloma related genital lesions in men.   
 
METHODS 
Study participants and sample collection 
Participants in this study were enrolled in the prospective HPV in Men (HIM) 
Study that examined the natural history of HPV infection in men.  To be eligible for 
enrollment, men had to meet the following criteria(a) 18-70 years old; (b) resided in 
Southern Florida, Sao Paulo, Brazil or the state of Morelos, Mexico; (c) reported no 
previous diagnosis of penile or anal cancer; (d) reported no prior diagnosis of genital or 
anal warts; (e) had not participated in an HPV vaccine clinical trial; (f) reported no prior 
diagnosis of HIV or AIDS; (g) were not currently being treated for an STI;  and (h) had 
not been imprisoned, homeless or in drug treatment in the previous 6 months.  A more 
detailed description of procedures in the HIM Study has been published previously [3, 4, 
35]. 
Men were examined by a trained clinician for the presence of external genital 
lesions at clinic visits that occurred every six months over four years.  Lesions that 
exhibited clinical features suggestive of condyloma were sampled for the presence of 
HPV DNA.  A pre-wetted Dacron swab was used to sample the surface of the lesion and 
a biopsy sample was also obtained.  Lesions with unknown etiology were also sampled, 
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although, lesions suspected to be non-HPV related such as Herpes Simplex Virus 
lesions, pearly penile papules, molluscum contagiosum, skin tags, and sebaceous 
glands were not sampled or biopsied.  Healthy genital skin was also sampled by 
combining swabs taken from the coronal sulcus/glans penis, penile shaft, and scrotum.  
Lesions were sampled before the healthy skin to avoid inter-specimen contamination.  
Patients with lesions suggestive of condyloma or dysplasia underwent removal by shave 
excision. Excised tissue was placed in 10% buffered formalin  and processed at the 
University of South Florida Dermatopathology Laboratory for pathologic interpretation by 
the study dermatopathologist, followed by DNA extraction for HPV genotyping.  
HPV detection and genotyping 
To test for the presence of HPV DNA in biopsied tissue, thin section microtomy 
specimens were cut from formalin-fixed paraffin-embedded tissue samples.  DNA was 
extracted from the tissue slice, after removal of paraffin by boiling and digestion with 
proteinase K, followed by precipitation of DNA with isopropanol using the QIAamp DNA 
FFPE Tissue procedure (Qiagen Inc – USA).  The INNO-LiPA HPV genotyping test 
(Innogenetics) was used to test for the presence of 24 HPV genotypes including 13 
oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) and 11 non-
oncogenic types (6, 11, 40, 42, 43, 44, 53, 54, 68, 70, and 74).   
DNA was extracted from swab samples of lesions and healthy skin samples 
using the QIAamp Mini kit following the manufacturer’s instructions (Qiagen, Valencia, 
CA).  The polymerase chain reaction consensus primer system PGMY 09/11 was used 
to amplify a fragment of the HPV L1 gene and test for the presence of HPV DNA.  The 
Linear Array HPV Genotyping Test (Roche Diagnostics, Indianapolis, IN) tested for the 
presence of 37 HPV genotypes including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, and 66) and 24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55, 
61, 62, 64,  67-73, 81–84, IS39, and CP6108).   
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A sample was considered HPV positive if HPV DNA was detected by PCR or 
tested positive for at least one HPV genotype.  Beta-globin was detected in 96% (47/49) 
of biopsies and 92% (36/39) of surface swab specimens.  The two biopsy samples 
negative for β-globin included one condyloma and one benign squamous keratosis 
lesion.  The three swab samples from the surface of lesions negative for β-globin were 
all benign squamous keratosis lesions.  Samples that tested negative for β-globin were 
not included in analyses.       
Statistical analysis 
  The prevalence of individual HPV types was calculated as the proportion of men 
who tested positive for each HPV type.  Sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) were calculated for individual HPV types to 
measure the accuracy of sampling the surface of a lesion as a marker of the HPV types 
present in the lesion tissue.  Sensitivity was calculated as the proportion of lesions with 
biopsy samples positive for a specific HPV type that also had swab samples from the 
surface of the lesion positive for the same HPV type.  Specificity was defined as the 
proportion of biopsy samples negative for a specific HPV type that also had swab 
samples negative for the same type.  PPV was calculated as the proportion of lesions 
with swab samples positive for an HPV type that also had a biopsy sample positive for 
the same HPV type.  NPV was the proportion of lesions with swab samples negative for 
an HPV type that also had a biopsy sample negative for the same HPV type.  Exact 95% 
confidence intervals based on the binomial distribution were calculated for all 
proportions.  Analyses were restricted to the 20 HPV types tested for in both the surface 
swab and biopsy samples (6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51-54, 56, 58, 59, 
66, and 68).  
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RESULTS 
In total, 34 lesions that tested β-globin positive for samples from both surface 
swabs and biopsies were included in these analyses.  The lesions included 19 
histologically confirmed condyloma and 15 lesions that did not demonstrate specific 
features of condyloma; diagnosis for these lesions was as follows: 13 benign squamous 
keratosis , one seborrheic keratosis lesion and one lichenoid tissue reaction.  The mean 
ages of men with condyloma and non-condyloma lesions were 28 (range, 18-49) and 29 
(range, 18-57), respectively.   
Table 1 presents the prevalence of HPV types detected in samples obtained from 
biopsies, the surface of lesions, and adjacent healthy genital skin for condyloma and 
non-condyloma lesions.  HPV DNA was detected in 95% of tissue samples obtained 
from condyloma.  The individual HPV types detected in the condyloma biopsies were 
HPV6 (63%), HPV11 (32%), and HPV16 (11%).  The prevalence of HPV DNA from 
swab samples taken from the surface of the condyloma was also 95%.  HPV6 (47%), 
HPV11 (37%), HPV16 (16%), and HPV18 (11%) were the types most commonly 
detected among condyloma swab samples.  Other HPV types including 40, 51, 53, 56, 
and 59 were detected on the surface of 26% of condyloma.  All swab samples taken 
from healthy genital skin adjacent to condyloma lesions were positive for HPV DNA.  
Consistent with the biopsy and surface swab samples, HPV6 (42%), HPV11 (37%), and 
HPV16 (26%) were the most common types detected, however, there was a higher 
prevalence of other HPV types (47%) than was observed in the tissue or surface swab 
samples.   
HPV DNA was detected in 93% of tissue samples from non-condyloma lesions 
with HPV6 (47%) and HPV11 (47%) being the most common types detected.  Other 
HPV types including 31, 33, 40, 51, 52, 53, and 58 were present in 20% of non-
condyloma biopsies.  Swab samples from the surface of non-condyloma lesions had 
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lower prevalence for any HPV DNA (60%), HPV6 (27%), HPV11 (13%), and HPV16 
(7%) than tissue samples.         
 Table 2 presents the sensitivity, specificity, PPV, and NPV of sampling the 
surface of lesions and adjacent healthy skin as markers for the HPV types detected in 
biopsy samples.  The sensitivity of swab samples from any type of lesion as a marker for 
HPV types in biopsied tissue for the corresponding lesion was 78% for any HPV, 63% 
for HPV6, 62% for HPV11, 50% for HPV16, and 33% for other HPV types.  Specificity of 
swab samples of the lesions was also high for HPV6 (93%), HPV11 (95%), HPV16 
(94%), and other HPV types (77%).  Samples from the surface of condyloma lesions 
were more sensitive than swabs from the surface of non-condyloma lesions for any HPV 
(94% vs. 57%), HPV6 (75% vs.43%), and HPV11 (100% vs. 29%).  Condyloma swabs 
were less sensitive for HPV16 (50%).  Swabs from both condyloma and non-condyloma 
lesions were highly specific for HPV6 (100% and.88%), HPV11 (92% and 100%), and 
HPV16 (88% and 100%).  Non-condyloma lesion swabs were not sensitive (33%), but 
were highly specific (83%) as markers of other HPV types in lesion tissue.  Similar to 
samples from the surface of lesions, swabs from adjacent healthy genital skin were more 
sensitive for HPV types in condyloma tissue than non-condyloma tissue.   
 Among condyloma lesions there was high PPV for swabbing the surface of the 
lesion for any HPV (94%), HPV6 (100%), and HPV11 (86%).  High PPV signifies a low 
rate of false positives for specific HPV types within the condyloma tissue when swabbing 
the surface of the lesion.  The frequency of false negatives was also low as indicated by 
high NPV for HPV6 (70%) and HPV11 (100%).       
 When different lesion types (i.e., condyloma vs. non-condyloma) were classified 
by visual inspection alone and not pathologically confirmed, 33 of the 34 lesions were 
diagnosed as condyloma.  Based on visual inspection, the sensitivity of swabbing the 
surface of the lesion for any HPV (81%) and HPV type 6 (63%) and 11 (67%) was lower 
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than among pathologically confirmed condyloma.  Specificity of HPV types 6 (93%) and 
11 (95%) however remained high among the condyloma diagnosed by visual inspection.        
 
DISCUSSION 
 To our knowledge, this is the first study to examine the concordance between 
HPV types detected on the surface and in the tissue of condyloma and non-condyloma 
genital lesions in men.  Swabs from the surface of condyloma were highly sensitive and 
specific as markers for HPV types present in condyloma tissue.  However, non-
condyloma lesions were less sensitive markers of HPV types in lesion tissue and may 
potentially underestimate the prevalence of individual HPV types within the lesion.   
HPV DNA was detected in 95% of condyloma tissue samples from the current 
study.  This is consistent with previous studies that biopsied condyloma and reported 
HPV prevalence estimates of 91% among women in the placebo arm of a vaccine trial 
[24] and 100% of men and women seeking treatment in a standard clinic setting [33].  
Likewise, HPV prevalence estimates ranged from 95% to 100% in studies that tested 
samples from swabbing the surface of the condyloma [26-28].  Also similar to our 
results, previous studies detected HPV 6/11 in 86% to 100% of condyloma [24, 26-28, 
33].  The finding that HPV16 was the third most common type detected in condyloma 
biopsies after HPV6 and HPV11 is consistent with previous studies that also reported a 
high (≥25%) prevalence of HPV16 [24, 33].  Among condyloma lesions, the prevalence 
of any HPV and types 6 and 11 was higher among the biopsy samples than samples 
from the surface of the lesion.  The sensitivities of the assays used to test the different 
sample types may account for some of this difference.  The INNO-LiPA assay used to 
test the biopsy samples is more sensitive for detecting HPV than the Linear Array assay 
used to test swabs from the surface of the lesion [44, 45], therefore prevalence of HPV is 
more likely to be higher for biopsy samples.          
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In this study, samples obtained from the surface of histologically confirmed 
condyloma were sensitive markers for the presence of HPV in condyloma tissue. 
However, in this study a significant number of lesions diagnosed as condyloma by visual 
inspection were not confirmed histologically. In the current study, visual inspection was 
94% sensitive and 23% specific for identifying histologically confirmed condyloma.  This 
apparent low specificity, however, likely relates to the difficulty of histologic diagnosis of 
early condyloma, since the non-condyloma lesions had the same rate of HPV detection 
by PCR as the condyloma lesions.  A significant number of these non-condyloma (13/15, 
87%) were given the diagnosis of “benign squamous keratosis,” a relatively non-specific 
pathologic diagnosis for lesions that show some but not all of the diagnostic criteria for 
HPV infection.  It is compelling that swabs of these non-condyloma lesions were found to 
be less sensitive as markers for the presence of HPV than the lesion tissue, a 
phenomenon which may relate to low viral load of these pathologically subtle lesions. 
Testing samples from the surface of condyloma diagnosed based on visual inspection 
alone may slightly underestimate the prevalence of HPV genotypes in condyloma.      
  Small sample size is a limitation in our analyses and may have contributed to 
the low sensitivity observed for some HPV types.  Samples from the surface of 
condyloma were only 50% sensitive to the presence of HPV16 in condyloma tissue.  
Since only two condyloma biopsies tested positive for HPV16, a larger sample size with 
a correspondingly higher prevalence of HPV16 might provide a more accurate measure 
of sensitivity for this genotype.  Given that most HPV genotypes were present in less 
than 10% of lesions, we were not able to assess concordance for individual HPV types 
other than 6, 11, and 16.  Future studies should confirm our findings using a larger 
sample size.   
 In summary, our results suggest that sampling the surface of a condyloma lesion 
is a non-invasive and accurate marker of HPV types present in condyloma tissue.  
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Therefore, it may not be necessary to add an invasive biopsy procedure to research 
protocols for studying condyloma in a standard clinic setting.     
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Table4.1.  Prevalence of HPV genotypes in samples from biopsies, the surface of lesions, and adjacent healthy genital skin 
for condyloma and non-condyloma genital lesions. 
 Biopsy samples Samples from the surface of the lesion Samples from adjacent healthy skin  
HPV 
genotype 
All lesions 
(N=34) 
Condyloma 
(N=19) 
Non-
condyloma 
(N=15) 
All lesions 
(N=34) 
Condyloma 
(N=19) 
Non-
condyloma 
(N=15) 
All lesions 
(N=34) 
Condyloma 
(N=19) 
Non-
condyloma 
(N=15) 
Any HPV 
type 32 (94%) 18 (95%) 14 (93%) 27 (79%) 18 (95%) 9 (60%) 31 (91%) 19 (100%) 12 (80%) 
6 19 (56%) 12 (63%) 7 (47%) 13 (38%) 9 (47%) 4 (27%) 12 (35%) 8 (42%) 4 (27%) 
11 13 (38%) 6 (32%) 7 (47%) 9 (26%) 7 (37%) 2 (13%) 10 (29%) 7 (37%) 3 (20%) 
16 2 (6%) 2 (11%) 0 (0%) 3 (9%) 3 (16%) 1 (7%) 6 (18%) 5 (26%) 1 (7%) 
18 0 (0%) 0 (0%) 0 (0%) 3 (9%) 2 (11%) 1 (7%) 4 (12%) 2 (11%) 2 (13%) 
Other 
HPV 
typesa 3 (9%) 0 (0%) 3 (20%) 8 (24%) 5 (26%) 3 (20%) 16 (47%) 9 (47%) 7 (47%) 
aIncludes HPV 31, 33, 39, 40, 42, 51, 52, 53, 54, 56, 58, 59, and 66. 
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Table 4.2.  Sensitivity, specificity, negative predictive value, and positive predictive value of samples from 
the surface of lesions and adjacent healthy skin as markers of HPV types present in biopsy samples in 
condyloma and non-condyloma genital lesions. 
 SWABS OF THE SURFACE OF THE LESION  SWABS OF ADJACENT HEALTHY SKIN 
 
All lesions 
(95% CI) 
Condyloma 
(95% CI) 
Non-
condyloma 
(95% CI)  
All lesions 
(95% CI) 
Condyloma 
(95% CI) 
Non-
condyloma 
(95% CI) 
Any HPV 
       
Sensitivity 78 (60-91) 94 (73-100) 57 (29-82)  91 (75-98) 100 (81-100) 79 (49-95) 
Specificity n/aa n/ab n/aa  n/aa n/aa n/aa 
PPV 93 (76-99) 94 (73-100) 89 (52-100)  94 (79-99) 95 (74-100) 92 (62-100) 
NPV 100 (59-100) n/ab 100 (54-100)  93 (75-99) 95 (74-100) 92 (62-100) 
HPV 6 
       
Sensitivity 63 (38-84) 75  (43-95) 43 (10-82)  58 (34-80) 67 (35-90) 43 (10-82) 
Specificity 93  (68-100 100 (59-100) 88 (47-100)  93 (68-100) 100 (59-100) 88 (47-100) 
PPV 92 (64-100) 100 (66-100) 75 (19-99)  92 (62-100) 100 (66-100) 75 (19-99) 
NPV 67 (43-85) 70 (35-93) 64 (31-89)  67 (43-85) 64 (31-89) 64 (31-89) 
HPV 11 
       
Sensitivity 62 (32-86) 100 (54-100) 29 (4-71)  69 (39-91) 100 (54-100) 43 (10-82) 
Specificity 95 (76-100) 92 (64-100) 100 (63-100)  95 (76-100) 92 (64-100) 100 (63-100) 
PPV 89 (52-100) 86 (42-100) 100 (16-100)  90 (56-100) 86 (42-100) 100 (16-100) 
NPV 80 (59-93) 100 (74-100) 62 (32-86)  80 (59-93) 100 (74-100) 67 (35-90) 
HPV 16 
       
Sensitivity 50 (1-99) 50 (1-99) n/ac  100 (16-100) 100 (16-100) n/ac 
Specificity 94 (79-100) 88 (64-99) 100 (78-100)  88 (71-96) 82 (57-96) 93 (68-100) 
PPV 33 (1-91) 33 (1-91) n/ac  33 (4-78) 33 (1-91) n/ac 
NPV 97 (83-100) 94 (70-100) 100 (78-100)  97 (83-100) 100 (77-100) 100 (77-100) 
HPV Othere 
       
Sensitivity 33 (9-91) n/ad 33 (1-91)  33 (1-91) n/ad 33 (1-91) 
Specificity 77 (59-90) 74 (49-91) 83 (52-98)  52 (33-70) 53 (29-76) 50 (21-79) 
PPV 13 (0-53) n/ad 33 (1-91)  6 (0-30) n/ad 33 (1-91) 
NPV 92 (75-99) 100 (77-100) 83 (52-98)  92 (75-99) 100 (69-100) 75 (35-97) 
Note: CI - confidence interval; PPV – positive predictive value; NPV – negative predictive value. 
aNot calculated due to small numbers.  
bNot calculated because no men with condyloma had skin swabs negative for HPV.  
cNot calculated because HPV16 was not detected in any non-condyloma biopsies.  
dNot calculated because other HPV types were not detected in any condyloma biopsies.   
eIncludes HPV 31, 33, 39, 40, 42, 51, 52, 53, 54, 56, 58, 59,and 66. 
 49
 
 
 
 
 
CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
SUMMARY OF FINDINGS 
 This study examined the natural history of HPV related condyloma in a cohort of 
2,487 men ages 18-70 from the US, Brazil, and Mexico enrolled in the prospective HIM 
Study.  This is one of the first studies to examine the progression from HPV infection to 
condyloma development and prospectively assess the sexual behavioral factors 
associated with condyloma in men.   
 The probability of developing a condyloma over 24-months was 5.2% and the 
median time to condyloma detection was 17.1 months.  HPV 6 and 11 were the HPV 
types most strongly associated with development of condyloma.  Men who had an 
incident HPV 6/11 infection had 12 times the risk of developing condyloma compared to 
men who were HPV negative.  Men with incident HPV 6/11 infections also had the 
highest probability of developing condyloma in a 24-month period (14.6%), and had the 
shortest time to detection of condyloma (median of 6.2 months).   
The surfaces of condyloma lesions were sampled to estimate the prevalence of 
HPV types in the condyloma.  HPV types 6, 11, and 16 were the most common types 
detected, however, the HPV types detected on the surface of lesions may not represent 
the HPV types present in the lesions themselves.  Nineteen pathologically confirmed 
condyloma with samples obtained from the surface of the lesion and biopsied tissue 
were genotyped to assess the concordance between HPV types detected on the surface 
and in the tissue of condyloma lesions.  Sampling the surface of condyloma was both 
highly sensitive and specific as a marker for the HPV types present in the condyloma 
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tissue.  Therefore, HPV prevalence estimates based on sampling the surface of lesions 
are likely accurate estimate of the HPV types present in lesion tissue.  
Recent sexual behavior was strongly associated with risk of developing 
condyloma.  Having three or more male anal sex partners in the previous three months 
was associated with an almost five times greater risk of condyloma compared to men 
with no male sexual partners.  Frequent vaginal intercourse and infrequent condom use 
during vaginal intercourse in the recent past also significantly increased the risk for 
condyloma.  Other factors associated with condyloma incidence were a high number of 
lifetime female partners, having a partner with condyloma, and ever being diagnosed 
with an STI.  Younger age was also a significant risk factor; men who were older than 
age 30 had a 50% reduced risk of condyloma compared to men ages 18-30.      
Multicollinearity could be present in multivariable regression models if two or 
more of the predictor variables in the model are highly correlated.  A high amount of 
multicollinearity would result in increased standard errors of the beta estimates and 
subsequent wide confidence intervals.  As a result, variables that are actually significant 
predictors would appear to have no significant association with the outcome.  The 
Pearson correlation coefficient values between pairs of the variables included in the final 
multivariable model (age, country, lifetime number of female partners, condom use, 
recent number of male sexual partners, frequency of vaginal intercourse, having a 
partner with condyloma, and having an STI) ranged from -0.02 to 0.21.  Given that no 
two variables in the model were highly correlated, it is not likely that a high degree of 
multicollinearity was present in the final multivariable model examining the factors 
associated with incident condyloma. 
Eight hazard regression models were run using the same dataset to examine the 
association between HPV infection with different HPV types and risk of condyloma.  The 
more HPV types that are examined in relation to condyloma risk, the greater the 
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likelihood that there will be a significant association observed simply by chance (i.e., 
type 1 error) due to multiple comparisons.  Multiple testing correction methods, such as 
Bonferroni, require that a p-value smaller than 0.05 be observed to declare an 
association is significant.  Though correction for multiple comparisons was not included 
in the models, a type 1 error is not likely given that the HRs for these models were very 
high and the corresponding p-values were often <0.0001.      
This study has limitations that need to be considered when interpreting the 
results.  Condyloma were identified by visual inspection and biopsy samples were not 
obtained to confirm that lesions were true condyloma.  Preliminary data from biopsy 
results collected in the HIM Study showed that compared to the gold standard of 
diagnosing condyloma by pathologic review, diagnosing condyloma by visual inspection 
was highly sensitive (94%), but not very specific (23%).  The low specificity suggests 
that some of the condyloma included in these analyses were actually non-HPV related 
skin conditions that resembled condyloma, such as benign squamous keratosis or 
seborrheic keratosis.  Despite the potential misclassification of diagnosing condyloma by 
visual inspection, most previous studies also did not have pathologically confirmation 
that lesions were condyloma.  Another limitation is the generalizability of the findings is 
likely limited due to the self-selection of participants.  Men who agree to participate in a 
four year prospective study may not be representative of the underlying population from 
each country.  However, our results are likely more generalizable than previous studies 
that were based on populations of men who have sex with men or men who were 
seeking treatment for an STI.    
Despite limitations, there are strengths of the study to note as well.  An extensive 
risk factor questionnaire was used to collect data on multiple lifetime and recent sexual 
behaviors.  The prospective study design allowed for measuring changes in sexual 
behavior over time.  Repeated measures of behavior were important given that recent 
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sexual behavior was strongly associated with risk of condyloma.  The prospective study 
design also allowed collection of data on sexual behavior before men developed 
condyloma.  Previous studies of risk factors for condyloma in men were case-control 
studies that collected risk factor data after men were diagnosed with condyloma.  This 
could bias results if being diagnosed with condyloma caused men to alter their sexual 
behavior (e.g., use condoms more frequently) or affected how accurately they recalled 
their sexual habits.  By collecting data on lifetime and recent sexual behavior before men 
were diagnosed with condyloma, we were able to minimize the chance of recall bias.   
  
FUTURE RESEARCH 
This study was one of the first to examine incidence and risk factors associated 
with condyloma in a prospective study largely including men from the general 
community, however, there are limitations that need to be addressed in future studies.  
The major limitation was identification of condyloma by visual inspection.  Future studies 
should biopsy suspected condyloma lesions to histologically confirm a lesion is 
condyloma and thereby minimize misclassification.  Condyloma incidence, time from 
HPV infection to condyloma development, and risk factors for condyloma should then be 
examined among histologically confirmed condyloma to assess if the results are 
consistent with studies that relied on diagnosis by visual inspection.   
Unclassified infections that tested positive for HPV DNA, but not for any specific 
HPV genotypes, were observed in 5% of condyloma in this study.  Cutaneous HPV 
types may account for some of the unclassified infections observed, however, no studies 
to date have utilized assays that test for the presence of cutaneous HPV in condyloma 
samples.  Futures studies should test for cutaneous in addition to mucosal HPV types in 
an effort to identify the unclassified genotypes present in condyloma.  
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The cohort used to examine risk factors for condyloma in this study included 
heterosexual men and men who have sex with men.  The placebo arm of an HPV 
vaccine clinical trial of men observed a significantly higher incidence of condyloma in 
men who have sex with men compared to men with only female sexual partners [14].       
Future studies should assess incidence of condyloma stratified by sexual orientation and 
examine whether the risk factors for condyloma differ between men who have sex with 
men and men who have sex with women only.  Differences in risk factors for condyloma 
by sexual orientation may warrant different prevention strategies that focus on modifying 
behavior in addition to vaccination.     
Though condyloma are the most common clinical manifestation of anogenital 
HPV infection, penile intraepithelial neoplasia (PIN), the pre-cursor lesion to 
approximately 50% of invasive penile carcinomas, is another HPV related external 
genital lesion that has not been studied extensively.  Since these lesions have the 
potential to develop into invasive cancer, it is important to identify risk factors associated 
with incidence of these lesions to create appropriate prevention strategies.  Accurate 
estimates of the prevalence of HPV types in PIN lesions is also needed to model the 
efficacy of the current HPV vaccine that protect against oncogenic HPV types 16 and 18.        
Another area that needs further study is the role of HPV antibodies in protecting 
against development of condyloma.  Using archived serum samples from HIM Study 
participants, a future study should examine whether HPV antibodies reduce the risk of 
condyloma by comparing condyloma incidence between men who are sero-negative and 
sero-positive for different HPV types.   
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APPENDIX A: LITERATURE REVIEW 
Human Papillomavirus 
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States, with an estimated 6.2 million new cases each year [1].  HPV is an 
established cause of cervical cancer and its precursor lesion, cervical intraepithelial 
neoplasia (CIN). The virus is also known to be associated with cancers at other sites 
including the oropharynx, anus, penis, vulva and vagina [2].  HPV related external 
genital lesions (EGL) in men include genital warts and penile intraepithelial neoplasia 
(PIN), a precursor lesion to some penile carcinomas.   
 Over 100 HPV types have been identified and approximately 40 of these types 
infect the anogenital region. HPV types are classified as non-oncogenic types (e.g. 6 
and 11) that are associated with benign conditions such as genital warts, and oncogenic 
types (e.g. 16, 18, 45, and 31) that are associated with intraepithelial neoplasia and 
invasive carcinoma.  The majority of HPV infections are asymptomatic and 70% of 
infections with clear within 12 months, however persistent infections can progress to 
dysplasia or invasive carcinoma [3]. 
 The quadrivalent vaccine Gardasil, that protects against HPV types 6, 11, 16, 
and 18, is currently available to women, and is effective at reducing the incidence of 
genital warts and precancerous lesions of the cervix, vulva and vagina [4].  In October 
2009, the U.S. Food and Drug Administration approved the use of Gardasil in men ages 
9 to 26.  The vaccine is currently being tested among men and has shown to be effective 
at reducing the incidence of HPV infection and genital warts in men ages 16-26 [5]. 
Vaccinating men may also reduce the incidence of HPV related penile dysplasia and 
penile carcinoma.  More data on HPV type distribution of male genital lesions and time 
from HPV infection to lesion development are needed to assess the potential impact of a 
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prophylactic vaccine in men, and to develop future vaccines that protect against 
additional HPV types. 
 To date, most research on the progression of HPV infection to disease has 
focused on women.  Little is known about the natural history of HPV related disease in 
men, including the HPV types associated with lesions, the rate of progression from HPV 
infection to lesion development, the proportion of type-specific HPV infections that 
progress to lesions and the sociodemographic and sexual behavior factors associated 
with the development of lesions.  Since male genital lesions are reservoirs for HPV 
infection, understanding the natural history of HPV related genital disease in men has 
the potential to not only reduce the burden of male disease, but also reduce the rate of 
HPV transmission to women. 
Genital HPV Infection in Men  
 A recent systematic review reported the prevalence of genital HPV DNA among 
men ranging from 1.3%-72.9% (with most studies reporting ≥20%) [6].  HPV prevalence 
varies widely across studies due to differences in the populations studied, genital sites 
sampled (e.g., scrotum, shaft, glans, etc.), and HPV DNA detection methods used. 
Prevalence tends to be higher in studies that use more sensitive DNA detection methods 
or sample for HPV DNA at multiple sites on the genitalia.  There are also differences 
across studies in the number of HPV types tested for.  Some studies only tested for HPV 
types 16 and 18, while other studies utilized assays that could detect more than 30 HPV 
types.  
 The multi-national HIM study (the source of the lesion data for this study) 
reported an overall HPV prevalence of 65.1% with a statistically significant higher 
prevalence in Brazil (72.3%) than the US (61.3%) or Mexico (61.9%) [7].  The HIM study 
prevalence estimate is based on sampling from four anatomic sites (coronal sulcus, 
glans, shaft, and scrotum) and testing for the presence of 37 types of HPV.   Among 
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men with HPV infections, 12.0% had oncogenic types only, 20.7% had non-oncogenic 
types only, 17.8% had both oncogenic and non-oncogenic types, and 14.7% had 
unclassified types only (tested positive for HPV by PCR, but negative for all of the 37 
mucosal HPV types tested for).  There was also a high rate of multiple infections 
(25.7%).  HPV 6 (6.6%) and HPV 16 (6.5%) were among the most common types, while 
HPV 11 (1.5%) and HPV 18 (1.7%) were detected less frequently.  Similar results were 
seen in a cross-sectional study of US men that examined HPV prevalence at six 
anogenital sites (glans/corona, penile shaft, scrotum, urethra, perianal area and anal 
canal) [8].  HPV was detected in 65.5% of men, with half the men (51.2%) testing 
positive for a known oncogenic or non-oncogenic type and another 14.3% testing 
positive for an unclassified HPV type. HPV 16 was the most common type detected 
(11.4%).  
Only a few cohort studies have examined the incidence and duration of HPV 
infection in men [9-14].  It is estimated that the cumulative incidence of male HPV 
infection over a 12-month period is between 29% and 39% [13, 14].  The majority of 
infections clear in less than 12 months, with one study of US men reporting a median 
time to clearance of 5.9 months [15]. 
The factors independently associated with HPV infection in men include not 
being circumcised [12, 15-18], lack of condom use [19-21], a history of having ever 
smoked [17, 19, 21], and a high number of lifetime sexual partners [15, 16, 19-21].  
Smoking impairs the humoral immune response (i.e., development of antibodies) to HPV 
infection [22].  An impaired immune response can increase the risk of becoming infected 
after being exposed to HPV or increase the likelihood of developing a persistent HPV 
infection.  Being circumcised may reduce the risk of infection by increasing the amount 
of keratinized epithelium present, which provides a more protective barrier than mucosal 
tissue against HPV infection.  Men who are not circumcised have a greater risk of micro 
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tears or abrasions (portals of entry for HPV) when the mucosal lining of the foreskin is 
exposed during intercourse [23].  
There does not appear to be an association between age and HPV prevalence in 
men. Studies consistently show that prevalence of HPV infection in men remains 
constant over the lifetime [6, 15, 19].  This is in contrast to the pattern observed in 
women, where HPV prevalence is highest among women 18-24 and then decreases 
until middle age, after which it remains steady for the remainder of the lifespan [24]. 
Epidemiology of Genital Warts 
Genital warts are a common sexually transmitted disease in the US, with an 
estimated 1 million new cases each year [25].  Data from private health plans estimate 
that the prevalence of genital warts is highest among men ages 25-29 and decreases 
with age [26].  Though there are no national data on the prevalence of genital warts in 
the US, in the 1999-2004 National Health and Nutrition Examination Survey, 5.6%  of 
sexually active adults ages 18-59 reported having ever been diagnosed with genital 
warts (7.2% women and 4.0% men) [27].  There are no precise estimates of genital wart 
incidence among men in the US.  
 Though genital warts are benign and not associated with mortality, they are a 
source of psychosocial distress, such as shame and embarrassment [28].  On rare 
occasions they can develop into malignant conditions such as Buschke–Lowenstein 
tumors or penile carcinoma [29].  Approximately 20-30% of genital warts will 
spontaneously regress [30], however recurrence of warts is common, resulting in high 
medical costs for repeated treatment.  An estimated $200 million is spent annually in the 
US for direct medical costs of genital wart treatment [31].     
 The incubation period is 3 weeks to 8 months, with most warts developing 2-3 
months after infection with HPV [32].  Genital warts are highly infectious and 
approximately 65% of people whose sexual partner has genital warts will develop warts 
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themselves [32].  Circumcised men are more likely to report a history of genital warts 
(4.5%) than uncircumcised men (2.4%) [27].  This is opposite from the association 
observed with HPV infection, where circumcised men are less likely to have HPV.  A 
possible explanation is that the uncircumcised men failed to detect genital warts that 
developed under the foreskin.  Among sexually active adults in the US, people who had 
>10 sexual partners in their lifetime had more than 7 times the odds of reporting a history 
of genital warts compared to adults with only 1 or 2 lifetime partners (OR=7.6; 95% CI: 
4.1-13.9) [27].     
HPV and Genital Warts 
More than 90% of genital warts are caused by non-oncogenic HPV types 6 and 
11 [29].  Data available for the HPV type distribution of genital warts in men are sparse. 
The largest case series to look at a broad range of HPV types in male genital warts 
included 135 men from Hong Kong [33].  HPV DNA was detected in 96% of the warts. 
Among HPV positive warts, 75.4% had non-oncogenic types only, 3.8% had oncogenic 
types only, and 20.8% had both oncogenic and non-oncogenic types.  There was a high 
rate of multiple infections (33.8%), often including coinfection with oncogenic types.  
HPV 6 was the most common type detected (54.6%), followed by HPV 11 (40.8%) and 
HPV 16 (6.2%).  A smaller case series of 12 men detected HPV in 100% of genital 
warts. Again, the most common HPV types were HPV 6 (75.0%), HPV 11 (16.7%) and 
HPV 16 (8.3%) [34].    
 HPV 6/11 have consistently been the most common types detected in genital 
warts.  Previous studies reported the HPV 6/11 prevalence in genital warts to be 86% 
among young women in the placebo arm of an HPV vaccine trial [35], 89% in men from 
Hong Kong [33], 90% among French men ages 18-72 [36], and greater than 95% in two 
small US studies that included fewer than 50 men [37, 38].  Oncogenic HPV types have 
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also commonly been detected in genital warts and several studies reported a high 
prevalence of HPV 16 [33, 35, 36, 38].         
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